Compare NUVL & AMKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | AMKR |
|---|---|---|
| Founded | 2017 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.7B |
| IPO Year | 2021 | 1998 |
| Metric | NUVL | AMKR |
|---|---|---|
| Price | $104.39 | $43.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $134.29 | $34.86 |
| AVG Volume (30 Days) | 828.0K | ★ 3.5M |
| Earning Date | 10-30-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.24 |
| Revenue | N/A | ★ $6,449,053,000.00 |
| Revenue This Year | N/A | $7.41 |
| Revenue Next Year | N/A | $9.14 |
| P/E Ratio | ★ N/A | $35.74 |
| Revenue Growth | N/A | ★ 0.14 |
| 52 Week Low | $55.54 | $14.03 |
| 52 Week High | $112.88 | $47.28 |
| Indicator | NUVL | AMKR |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 64.96 |
| Support Level | $103.52 | $30.03 |
| Resistance Level | $107.99 | $47.28 |
| Average True Range (ATR) | 3.18 | 1.95 |
| MACD | -0.93 | 0.49 |
| Stochastic Oscillator | 10.43 | 76.61 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.